Goldman Sachs analyst Corinne Johnson resumes coverage on Neurocrine Bio. (NASDAQ: NBIX) with a Buy rating and a price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage